Indication
Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Loading your page…
Marketing Authorisation Holder: Biosimilar Collaborations Ireland Limited
EMA Authorisation: 20/11/2018
INN: pegfilgrastim
AI Drug & Interaction Analysis
Free account required
Ask Osler about Fulphila: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.